Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
about
Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growthA newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosisCD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cellsA cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosisDifferential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamilyRespiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligandIrradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosisRoles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseOnto better TRAILs for cancer treatmentGetting TRAIL back on track for cancer therapyCrystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificityMechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell typesIn chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areasTranscription initiation sites and promoter structure of the human TRAIL-R3 geneTRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signallingIG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISCFollowing a TRAIL: update on a ligand and its five receptorsGeneral Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMACCARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cellsTROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with Edar and is expressed in embryonic skin and hair folliclesInducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectinEarly therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopySynergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer.Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy fluxTargeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination.CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation.Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.Role of p53 family members in apoptosis.Safety and antitumor activity of recombinant soluble Apo2 ligand.Maternal plasma soluble TRAIL is decreased in preeclampsia.Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function.
P2860
Q22003914-73542220-7AB2-4D1B-9382-E02829A2FC47Q22009531-B5D6221A-FA35-4F97-9B2F-3696B1918657Q24291469-FDBE1BCC-18B7-47B9-864A-95C24B1D46CFQ24319367-3D81A683-5DED-499A-ACBF-724A57C00B96Q24654366-F4D0B080-5D35-4835-9F85-B6A1330AAFDBQ24683245-5F904CA4-9335-4820-923E-CAFC6FAD102EQ24798681-2DE5C708-5EE2-476D-99EB-535ECB863964Q26747224-DD3AC28E-2DE0-495F-879D-C9BB1A99D1EBQ26768160-80190C70-D915-4C88-B232-4DB1DCA5ACC6Q27027460-BD7447C2-427D-4BAB-855B-6937B0AEA345Q27625357-E5D8C3E7-973B-4FA9-A300-4E3AE50FAA6FQ28140698-75BACB32-B3CA-4E04-97DE-FED307E21C7BQ28179380-0CFFE13E-10E5-43AD-806A-5BB5A801FB41Q28213507-CF6AF461-01C6-463F-AAC2-BE711BD060D1Q28267294-FC6BFC1C-6E6A-4661-A16A-4B39B3CF279AQ28267857-B61F8FC4-77F5-4DF0-A21D-BFF1266186EAQ28292767-5F7A18DA-BC7C-45D4-A4F7-07E61372B1F7Q28385542-96D66363-80A1-4F9B-8E84-21A0C2380376Q28396942-766EABD7-F77F-4E69-B586-28B6941FB133Q28512952-E2F00757-E1F5-4B2B-8DDF-1DF46C14E6FDQ30523992-99EAD727-D0A3-47A2-8058-B39F98DD1E9BQ30682911-2C65D7C2-7EE0-4DD2-B45A-21E5B9540CDAQ31145220-0758E520-6A5A-4FEA-9641-48C73564261DQ33180363-FB137D3B-AB81-488E-BAC0-5EC59BAC72A6Q33523440-86F0ADCC-345F-490D-A61B-8AF7FD5914E0Q33591623-9125AF4A-4D53-426B-847D-A5DB38E3555CQ33650479-02EFF392-1D7D-4A11-BC99-628435F48708Q33688828-9008D4C0-6283-485B-810B-3F846D731D23Q33726537-8A2C251F-F582-4372-9A56-C6112F004ABBQ33729242-02D17465-4FBA-4638-85A1-4E7F770C79BBQ33740931-E7E4D055-CF6D-4DA0-8C45-9A8EAB6E1733Q33747241-F846E27A-274C-494B-BCD9-000552487844Q33782305-BCCFAAEA-AAC6-4212-95C3-3151A937FD86Q33810088-AE7DB7F4-F044-4BE6-BB8E-A662502A5BAEQ33855449-3F8A30AF-9DA8-4C2E-A727-FFD1FD78C005Q33909572-1A67B0D7-15D1-4A1A-98DD-40CB15C51E80Q33910907-B5536997-3E21-4A00-A8A4-9D82C11F5256Q33912038-4AC818BE-B40F-488A-9748-AF6C2BE234D7Q33999606-5B1C699A-2E51-464F-A01B-220C856598D6Q34071289-47313000-2757-4CAA-9DE8-F79B7D5A62B7
P2860
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Cloning and characterization o ...... emerging TRAIL receptor family
@ast
Cloning and characterization o ...... emerging TRAIL receptor family
@en
Cloning and characterization o ...... emerging TRAIL receptor family
@en-gb
Cloning and characterization o ...... emerging TRAIL receptor family
@nl
type
label
Cloning and characterization o ...... emerging TRAIL receptor family
@ast
Cloning and characterization o ...... emerging TRAIL receptor family
@en
Cloning and characterization o ...... emerging TRAIL receptor family
@en-gb
Cloning and characterization o ...... emerging TRAIL receptor family
@nl
prefLabel
Cloning and characterization o ...... emerging TRAIL receptor family
@ast
Cloning and characterization o ...... emerging TRAIL receptor family
@en
Cloning and characterization o ...... emerging TRAIL receptor family
@en-gb
Cloning and characterization o ...... emerging TRAIL receptor family
@nl
P2093
P2860
P3181
P356
P1476
Cloning and characterization o ...... emerging TRAIL receptor family
@en
P2093
M A Degli-Esposti
P J Smolak
R F DuBose
R G Goodwin
P2860
P304
P3181
P356
10.1084/JEM.186.7.1165
P407
P577
1997-10-06T00:00:00Z